Mr. Nicholas Kadysh reports

PHARMALA ISSUES Q3 FINANCIAL STATEMENTS AND AGM UPDATE

Pharmala Biotech Holdings Inc. has publicly filed its financial and operational results for the period ended May 31, 2026. All figures are reported in Canadian dollars. The company's full set of unaudited condensed interim consolidated financial statements for the quarter and accompanying management discussion and analysis can be accessed by visiting the company's website and its profile page on SEDAR+.

"Pharmala's financial position continues to improve compared to 2025, in line with the broader growth of the biotech industry," said Nick Kadysh, chief executive officer of Pharmala Biotech. "We were pleased to execute an excellent quarter of sales as well as our transaction with Jupiter Neuroscience, first announced in Q3 and executed as a subsequent event in Q4."

Financial highlights:

• Revenues for the nine months ended May 31, 2026, topped $1-million, compared with $338,000 in the comparable nine months ended May 31, 2025 (three months ended May 31, 2026: $513,000, compared with 2025: $135,000).
• Net loss and comprehensive loss for the three and nine months ended May 31, 2026, were $499,759 and $1,247,150, compared with $524,235 and $1,814,110 for the three and nine months ended May 31, 2025, primarily due to the increase in revenue.
• Cash used in operating activities was $673,588 for the nine months ended May 31, 2026, compared with $748,758 for the nine months ended May 31, 2025.

"While we have capitalized on opportunities in making strategic product sales, we are far more excited about our recent licensing agreements," said Will Avery, chief financial officer of Pharmala Biotech. "Long term, licensing agreements present not only further revenue opportunities but also reflect the potential upside value of our research and development engine."

Annual general meeting update

Pharmala would like to thank all shareholders who participated in the company's annual general meeting and is pleased that all motions recommended by management were duly passed.

About Pharmala Biotech Holdings Inc.

Pharmala is a biotechnology company focused on the research, development and manufacturing of MDXX-class molecules, including MDMA (3,4-methylenedioxymethamphetamine). Pharmala was founded with a dual focus: alleviating the global backlog of generic, clinical-grade MDMA to enable clinical trials as well as commercial sales in selected jurisdictions and to develop novel drugs in the same class. Pharmala is the only company currently provisioning clinical-grade MDMA for patient treatments outside of clinical trials. Pharmala's research and development unit has completed proof-of-concept research into several IP (intellectual property) families, including ALA-002, its lead drug candidate. Pharmala is a regulatory-first organization, formed under the principle that true success in the psychedelics industry will only be achieved through excellent relationships with regulators.

We seek Safe Harbor.